Clinical Research Directory
Browse clinical research sites, groups, and studies.
Switching From Restasis to TRYPTYR
Sponsor: Southern College of Optometry
Summary
Switching to acoltremon 0.003% will significantly improve the signs and symptoms of participants who were being treated with Restasis at 28 days post-treatment compared to baseline. Dry eye disease (DED) is a prevalent condition that commonly affects patients of working age in addition to the elderly. DED is a complex condition that results in ocular symptoms such as dryness and burning and signs such as decreased tear production (aqueous deficient DED) or increased tear evaporation (evaporative DED). Unfortunately, there is not a perfect correlation between DED signs and symptoms, which makes diagnosis and timely treatment challenging.
Official title: Efficacy of Switching Participants Treated With Restasis to TRYPTYR
Key Details
Gender
All
Age Range
18 Years - 100 Years
Study Type
INTERVENTIONAL
Enrollment
100
Start Date
2025-12-01
Completion Date
2026-05-15
Last Updated
2025-12-05
Healthy Volunteers
No
Conditions
Interventions
acoltremon 0.003%
Participants who are using restasis will be switched to acoltremon 0.003%